Filing Flows › CorMedix (CRMD) › Q2 2026
CorMedix (CRMD) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
CorMedix (CRMD) reported revenue of $102M for the second quarter 2026 (Q2 2026), +157% from a year earlier and -20% from the quarter before. Operating margin was 42.1%, net earnings $26.0M (25.5% of revenue).
CorMedix, Q2 2026: revenue $102M (+156% year over year), operating margin 42.1%, net earnings $26.0M, operating cash flow $86.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $102M | -20% | +157% |
| Gross profit | $77.1M | -27% | +104% |
| Operating profit | $42.9M | -33% | +120% |
| Net earnings | $26.0M | -33% | +31% |
| Operating cash flow | $86.2M | +103% | +188% |
| Free cash flow | $85.7M | +106% | +186% |
What changed
Revenue was $101.9M in Q2 2026, up 157% year over year and down 20% from the previous quarter. DefenCath was the largest line at 65% of revenue. DefenCath added $26.4M year over year (up 66%), 42% of the total change.
Gross margin was 75.7%, down 19.6 points from Q2 2025. Operating profit was $42.9M, a 42.1% margin (down 7.1 points year over year). Of the extra revenue versus Q2 2025, 38% reached operating profit, below the 49% margin then. Operating expenses grew 87% against revenue growth of 157%. The fastest-growing cost line was Research & development (+174%). Net earnings were $26.0M, up 31% year over year. The effective tax rate was 32.9%.
Operating cash flow was $86.2M (up 188% year over year), 332% of net earnings. Non-cash charges added back $10.5M of depreciation and amortization and $4.1M of share-based compensation. Working capital and other items added $45.6M. Capital expenditures of $561K left free cash flow of $85.7M.
Questions
What was CorMedix's revenue in the second quarter 2026?
CorMedix (CRMD) reported revenue of $102M for the second quarter 2026 (Q2 2026), +157% from a year earlier and -20% from the quarter before.
Was CorMedix profitable in the second quarter 2026?
Operating profit was $42.9M (42.1% of revenue) and net earnings $26.0M.
Source: CorMedix 10-Q on SEC EDGAR.